Clinical Trial Update: Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating binimetinib with nivolumab, with or without ipilimumab, in previously treated microsatellite-stable colorectal cancer with RAS mutation…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Binimetinib (binimetinib)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Pfizer | Conditions: MSS, RAS-mutant Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-11-02